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A B S T R A C T
Background: Hyper-IgD and periodic fever syndrome
(HIDS) is an hereditary autoinflammatory syndrome,
characterised by recurrent inflammatory attacks. Treatment
of HIDS is difficult, although simvastatin is beneficial
and etanercept might be effective. Studying the treatment
of a rare periodic syndrome is complicated by the varying
frequency and severity of symptoms and low prevalence.
Our aim was to develop a system of clinical observations
to evaluate effectiveness of treatment-on-demand. 
Methods: Seven fever episodes in three HIDS patients were
monitored, with and without administration of etanercept
or anakinra. We developed a clinical score, which includes
12 symptoms. In one patient, inflammatory attacks were
provoked by vaccination. 
Results and conclusions: At the onset of an attack, all
patients reported a clinical score between 20 and 25. The
score was used to quantify severity and define the end of an
attack. Reproducible monitoring of inflammatory episodes
was difficult, even in this pilot study. The effect of early
administration of etanercept was variable. In one patient,
a fever episode could be readily provoked within 12 to 24
hours by vaccination. In this patient, the IL-1ra analogue
anakinra was more successful in aborting the inflammatory
attack than etanercept. We propose that this vaccination
model will allow evaluation of treatment-on-demand in a
controlled setting.
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I N T R O D U C T I O N
The hyper-IgD and periodic fever syndrome (HIDS,
MIM#260920) is an autosomal recessively inherited
autoinflammatory syndrome, caused by deficient enzyme
activity of mevalonate kinase, an enzyme in the isoprenoid
pathway. Patients present with a long history of recurrent
fever attacks, lasting three to seven days, accompanied by
chills, headache, generalised lymphadenopathy, arthralgia,
skin lesions, abdominal pain and diarrhoea. Laboratory
analysis reveals an intense acute-phase response during
fever attack; ex-vivo production of tumour necrosis factor
(TNF)- and interleukin (IL)-1 by monocytes and
macrophages is significantly higher at the time of attack.1
An attack is usually preceded by a well-recognisable pro-
dromal phase of malaise, headache and musculoskeletal
symptoms.2 Sometimes, a (trivial) stimulus can be identified
as a trigger of the attack, and most HIDS patients experience
a severe inflammatory episode after any vaccination. In
between two attacks patients are asymptomatic, although
the acute-phase response may sometimes persist. 
Until now, treatment of HIDS patients is largely supportive
and very difficult. Various standard anti-inflammatory drugs
(including colchicine, NSAIDS, steroids and thalidomide)
have failed to suppress the attacks.2,3 We have already shown
that simvastatin, an inhibitor of HMG-CoA reductase, can
be beneficial in reducing the number of days of illness
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when taken continuously.4 Reports on the response to
etanercept, an inhibitor of TNF, in HIDS have been
mixed: favourable in two children,5 uncertain in one,6 and
no effect in another child.7
Studying the effectiveness of a treatment for a rare periodic
syndrome is complicated by its variability of frequency
and severity of symptoms and its low prevalence. We have
tried to develop a system of rigorous clinical observations
to evaluate the effectiveness of treatment-on-demand.
M E T H O D S
Three female Dutch HIDS patients gave written informed
consent for participation in this study; the study was
approved by the local medical ethical committee. The
patients were not on any medication apart from that
mentioned in the case observations. They were instructed
to contact us at the first indication of a fever attack. When
that happened, the patient was admitted to hospital for
close monitoring, which included regular measurement
of body temperature and blood sampling for C-reactive
protein (CRP). 
We asked the patients to complete a daily symptom score
card, rating the absence or presence of 12 different symp-
toms and their severity on a scale from 0 to 10. These
12 symptoms were lymphadenopathy, nausea, myalgia,
arthralgia, aphthous ulcers, abdominal pain, skin lesions,
headache, sore throat, tiredness, diarrhoea and nasal
congestion. This was used to develop a clinical scoring
system to help better delineate the duration and severity
of a fever episode. By adding the scores on the individual
symptoms, a daily score could thus range from 0 to 120.
At the height of a fever episode, patients experienced
between 7 and 12 of these 12 symptoms, while the maximal
documented score ranged from 45 to 88 points. Despite
an anticipated variability in scores between patients and
between separate attacks in the same patient, all patients
reported a total score between 20 and 25 at the time of
presentation at the start of a fever attack. Thus, a score of
20 or higher was taken to represent the presence of a
fever attack, while the time point of the first score below
20 was taken as the end of the attack. 
C A S E  O B S E R V A T I O N S
Patient 1 
A 35-year-old woman had experienced characteristic febrile
attacks since the age of 3 months. At age 33, HIDS was
finally diagnosed, confirmed by mevalonate kinase mutation
analysis (table 1). During childhood, vaccinations used to
trigger febrile attacks but the administration of hepatitis
A immunoglobulin at the age of 34 years did not precipitate
any symptoms. She was closely monitored during an
attack which started with a sore throat, myalgias, fatigue,
nausea and headache (figure 1A). Her body temperature was
36.6°C at presentation. Over the next few days symptoms
increased and her body temperature quickly rose to 39.5°C,
with a maximum CRP of 102 mg/l. The symptoms of the
attack lasted four days although serum CRP concentration
was still elevated at seven days (figure 1A). 
The next time she was admitted at the start of a fever
attack, two doses of etanercept (25 mg) were administered
subcutaneously at 12 and 36 hours after presentation
(figure 1B). There was no noticeable difference in her clinical
symptoms as expressed in the clinical score, body tempera-
ture or decrease in CRP concentration between this fever
episode and the previous, untreated one (figure 1). 
Patient 2 
In this 26-year-old woman the diagnosis of HIDS was made
three years ago, after she had experienced fever episodes
since two months after birth. Childhood vaccinations
consistently precipitated febrile attacks. The diagnosis was
confirmed by mutation analysis, and an immeasurably
low mevalonate kinase enzyme activity (table 1). 
The attack during which she was monitored appeared to
be uncommonly severe with respect to the accompanying
symptoms. She did not receive treatment during this
attack which lasted seven days; she experienced massive
cervical and iliac lymphadenopathy and developed oral
and vaginal aphthous ulcers. CRP concentration rose to
a maximum of 315 mg/l after 72 hours, while her body
temperature was maximally 38.4°C (figure 2A). 
A subsequent fever episode is depicted in figure 2B. The
patient only reached our hospital some 48 hours after onset
of symptoms, and immediately after admission etanercept
Bodar, et al. Treatment evaluation in HIDS.
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Table 1 Patient characteristics
Case Age (years) Age at onset Mevalonate Mevalonate Serum IgD 
(months) kinase genotype kinase enzyme activity* (U/ml†)
1 35 3 V377I/G202R ND 2330
2 26 2 V377I/417insC <0.1% 745
3 38 1 V377I/I268T 10.7% 616
*Expressed as % of normal; †reference value IgD <100 U/ml; ND = not determined.
treatment was initiated. At that time, serum CRP concen-
tration was similar to that at 48 hours into the first attack
(263 vs 252 mg/l), as was her clinical score (74 vs 71 points)
(figure 2). After institution of treatment, the CRP concentra-
tion declined steadily, and within three days her symptoms
had disappeared (figure 2B). Thus, etanercept seemed to
shorten this attack in comparison with the previous one.
The patient maintained that the second attack was milder
and she was unconvinced of a beneficial effect.
Patient 3
Patient 3 is a 38-year-old woman with fever episodes since
birth (table 1). She was admitted to the hospital for obser-
vation of an untreated fever episode. On admission, she
complained of myalgia, arthralgia, abdominal pain and
skin lesions. Her body temperature was 36.8°C, but rose
to above 39°C within two days (figure 3A). The symptomatic
attack persisted for six days, with a concomitant rise and
fall of CRP concentration. 
Because of a planned trip to China she required several
vaccinations, and given her earlier childhood experiences
of fever attacks after vaccinations, we decided to admit
her for administration of the injections. We gave her one
vaccination for hepatitis A (a primo vaccination in her
case) and one (repeat) DTP toxin vaccination, separated
by one month. Some 24 to 48 hours after administration
of each vaccine she developed a characteristic HIDS attack
with fever, abdominal pain, myalgia and fatigue. In both
instances this was accompanied by an intense acute-phase
response (maximum CRP 166 mg/l; figures 3B and 3C).
We used this model of vaccination-precipitated HIDS
attack to test the efficacy of early institution of treatment
to abort the fever episode. In the first attack, two doses of
etanercept (25 mg, subcutaneously) were administered
72 and 86 hours after vaccination (48 and 72 hours after
onset of the first symptoms). The symptomatic attack lasted
for 5.5 days in total, with maximum CRP concentration
reaching 36 hours after the first dose of etanercept (figure 3B).
At the next vaccination one month later, we administered
anakinra, a recombinant selective  IL-1 receptor antagonist
(100 mg per dose, subcutaneously), at three time points
from 72 hours after vaccination, with an interval of 24 hours.
Body temperature normalised and symptoms disappeared
within 17 hours after the first injection, peak CRP concen-
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Figure 1 Two inflammatory attacks in patient 1
= Serum CRP concentration (mg/l) on left Y-axis; = body temper-
ature (°C) on right Y-axis; = total clinical score on left Y-axis; grey
area depicts area of clinical score below 20 points. a) untreated
inflammatory episode; b) inflammatory episode treated with etanercept
at 12 and 36 hours after onset of symptoms (denoted by arrows).
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Figure 2 Two inflammatory attacks in patient 2
= Serum CRP concentration (mg/l) on left Y-axis; = body temper-
ature (°C) on right Y-axis; = total clinical score on left Y-axis; grey
area depicts area of clinical score below 20 points. One untreated
inflammatory episode (a), and one inflammatory episode treated
with etanercept (b, denoted by arrows).
tration was reached at 12 hours after the first injection
and CRP gradually returned to baseline values (figure 3C).
Thus, anakinra aborted the attack after some three days
of symptoms, in contrast to the 5.5 and 6 days of the other
witnessed attacks. 
Antibody titres were found to be adequate after both
vaccinations (data not shown), thus demonstrating that
the administration of cytokine antagonists 72 hours after
vaccination did not have an influence on the effectiveness
of the vaccinations.
D I S C U S S I O N
In this pilot study monitoring fever attacks in HIDS, we
closely followed seven fever episodes in three patients,
with and without intervention. 
To quantify the accompanying symptoms of the inflam-
matory attack, we developed a clinical scoring system
consisting of the total scores on a visual analogue scale
on a range of 12 symptoms and signs. At the moment the
patients felt the onset of a fever attack, they documented
a total score of between 20 and 25. Since concentration of
CRP and some of the symptoms, most notably tiredness,
may persist for a longer period, the end of a HIDS attack
may be difficult to define. We found that the proposed
clinical score may help with this as well: we suggest defining
the end of the attack as the moment at which the clinical
score decreases to 20 or less.
The results of monitoring fever episodes in patients 1 and 2
demonstrate the variability of this disorder. It was our aim
to start with intervention at the earliest possible moment
and we therefore instructed patients to contact us as soon
as possible after the start of symptoms. However, even in
our small pilot study there was a difference of 36 hours
between the time of first administration of etanercept in
the two patients. The wide variation seriously impedes
the comparability of results in a larger trial set-up. Part of
the delay was caused by the fact that we admitted patients
to our clinic, which might also induce a selection bias
towards more severe attacks. However, treatment at home
would make it more difficult to objectively observe
symptoms, body temperature and CRP concentrations.
A HIDS patient who needed vaccinations allowed us to
observe the power of these vaccinations to provoke a fever
episode. In both instances, vaccination resulted in a fever
episode within 12 to 24 hours. These attacks were compa-
rable with attacks not precipitated by vaccinations. There
are some advantages to using this provocation model: it is
simple, easy to use and offers an opportunity to closely
monitor the onset of the attack from the very beginning, and
thus to standardise the time to starting treatment. Since
patients are hesitant to receive (necessary) vaccinations
because of the risk of a febrile attack, a closely monitored
setting will be helpful to ensure that they do receive them. 
With respect to the observations of effect of treatment-on-
demand in these patients: these first results appear to be
mixed, and this pilot study does not allow us to draw firm
conclusions on that point. Anakinra seems to be more
Bodar, et al. Treatment evaluation in HIDS.
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Figure 3 Inflammatory attacks in patient 3
= Serum CRP concentration (mg/l) on left Y-axis; = body temper-
ature (°C) on right Y-axis; = total clinical score on left Y-axis; grey
area depicts area of clinical score below 20 points. a) untreated
inflammatory episode; b) inflammatory episode provoked by hepatitis
A vaccination, and treated with etanercept (denoted by arrows); c)
inflammatory episode provoked by DTP vaccination, and treated
with anakinra (denoted by arrows).
successful than etanercept; this warrants further exami-
nation. HIDS is part of a group of hereditary autoinflam-
matory syndromes,8 whose common pathogenic background
seems to involve IL-1 signalling. Recently several groups
have reported treating hereditary autoinflammatory syn-
dromes successfully with the recombinant form of IL-1ra,
anakinra.9-13
It remains difficult to get solid evidence on treatment
efficacy in orphan diseases, especially when periodic and
variable in phenotype, such as HIDS. Most published
reports concern clinical observations in one or two patients.
Drug trials set up on established lines such as randomised
controlled trials will often remain underpowered because
of too few patients and too few episodes of illness.3,4 Also,
because the frequency of fever attacks in adult HIDS
patients will usually diminish to between 6 and 12 per year,
patients will be more interested in an on-demand treatment
which shortens an attack than in continuous treatment
(and continuous life-long risk of side effects), unless this
continuous treatment will abolish all further symptoms.
We suggest that the vaccination provocation model in
combination with the clinical score described in this pilot
study will offer an opportunity for more rigorous and
standardised study of on-demand treatment in HIDS.
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